CAJ | 학술논문

131Ⅰ-肿瘤细胞核人鼠嵌合单克隆抗体(131Ⅰ-chTNT)以肿瘤的坏死区域为靶目标,因其靶抗原广泛存在于细胞核中,突破了传统放射免疫治疗中核素标记的单克隆抗体仅能以肿瘤细胞表面抗原为靶向的局限性,从而可实现对肺癌、肝癌、大肠癌及神经胶质瘤等多种实体瘤的有效治疗.131Ⅰ-chTNT与现有放、化疗及射频消融方法等联合应用,可增加肿瘤坏死区域,暴露更多结合靶点,使131Ⅰ-chTNT治疗实体瘤取得更好的疗效.
131Ⅰ-종류세포핵인서감합단극륭항체(131Ⅰ-chTNT)이종류적배사구역위파목표,인기파항원엄범존재우세포핵중,돌파료전통방사면역치료중핵소표기적단극륭항체부능이종류세포표면항원위파향적국한성,종이가실현대폐암、간암、대장암급신경효질류등다충실체류적유효치료.131Ⅰ-chTNT여현유방、화료급사빈소융방법등연합응용,가증가종류배사구역,폭로경다결합파점,사131Ⅰ-chTNT치료실체류취득경호적료효.
131Ⅰ labeled mouse-human chimeric tumor necrosis therapy monoclonal antibody (131Ⅰ-chTNT) is a kind of new drug targeting at degenerated or necrotic nuclei in the tumor necrosis zone,and may be applicable to the majority of human solid tumors,such as lung cancer,liver cancer,colon carcinoma and glioma,while conventional tumor cell monoclonal antibody can target only tumor cell surface antigen.Enhanced effects can be achieved by 131Ⅰ-chTNT in combination with other therapies,such as radiotherapy,chemotherapy or radiofrequency ablation,which may increase tumor necrosis region and expose more combinative targets.